Psychedelics like psilocybin, MDMA, and ketamine are emerging as promising therapeutic tools for mental health issues. Here's ...

Treatment-resistant depression is a term used to describe a form of major depressive disorder ... The amygdala is a small, almond-shaped structure in the brain’s temporal lobe that is involved in ...

Proven Success for Treatment-Resistant Conditions Many individuals in NYC have turned to ketamine therapy ... These options ...

Atai Life Sciences N.V. ( (ATAI) ) has released its Q3 earnings. Here is a breakdown of the information Atai Life Sciences N.V. presented to ...

Roche has entered into an agreement with Evotec to fund the Phase II clinical development of a selective N-methyl-D-aspartate (NMDA) receptor antagonist, EVT 101, for patients with treatment ...

Psilocybin therapy -- used to treat a range of mental health conditions, such as depression, anxiety, and addictions -- can ...

A study published in the Journal of Psychopharmacology has found that feelings of relaxation, rather than mystical ...

By targeting complex conditions such as treatment-resistant depression, social anxiety disorder and opioid use disorder, Atai aims to address significant gaps in the mental health treatment landscape.

It is neither possible nor desirable to eliminate anxiety entirely, as it plays a crucial role in keeping us alert and alive. Treatment is geared to keeping anxiety at manageable levels.

The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to ...